REGENERON PHARMACEUTICALS, INC. Revenues
REGENERON PHARMACEUTICALS, INC. (REGN) reported Revenues of $1.51 billion for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2018-05-03
- REGENERON PHARMACEUTICALS, INC. revenues for the quarter ending 2018-03-31 was $1.51B, a 14.59% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. revenues for the quarter ending 2017-12-31 was $1.58B, a 28.99% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. revenues for the quarter ending 2017-09-30 was $1.50B, a 22.99% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. revenues for the quarter ending 2017-06-30 was $1.47B, a 21.23% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. revenues for fiscal 2017 was $5.87B, a 20.82% increase from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. revenues for fiscal 2016 was $4.86B, a 18.44% increase from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. revenues for fiscal 2015 was $4.10B, a 45.55% increase from fiscal 2014.
- REGENERON PHARMACEUTICALS, INC. revenues for fiscal 2014 was $2.82B, a 33.96% increase from fiscal 2013.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2018-03-31 | $1.51B 10-Q · filed 2018-05-03 | $3.09B derived: sum of 2 quarters · filed 2018-05-03 | $4.59B derived: sum of 3 quarters · filed 2018-05-03 | $6.06B derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-12-31 | $1.58B 10-K · filed 2018-02-08 | $3.08B derived: sum of 2 quarters · filed 2018-02-08 | $4.55B derived: sum of 3 quarters · filed 2018-02-08 | $5.87B 10-K · filed 2018-02-08 |
| 2017-09-30 | $1.50B 10-K · filed 2018-02-08 | $2.97B derived: sum of 2 quarters · filed 2018-02-08 | $4.29B 10-Q · filed 2017-11-08 | $5.52B derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-06-30 | $1.47B 10-K · filed 2018-02-08 | $2.79B 10-Q · filed 2017-08-03 | $4.02B derived: sum of 3 quarters · filed 2018-05-03 | $5.24B derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-03-31 | $1.32B 10-Q · filed 2018-05-03 | $2.55B derived: sum of 2 quarters · filed 2018-05-03 | $3.77B derived: sum of 3 quarters · filed 2018-05-03 | $4.98B derived: sum of 4 quarters · filed 2018-05-03 |
| 2016-12-31 | $1.23B 10-K · filed 2018-02-08 | $2.45B derived: sum of 2 quarters · filed 2018-02-08 | $3.66B derived: sum of 3 quarters · filed 2018-02-08 | $4.86B 10-K · filed 2018-02-08 |
| 2016-09-30 | $1.22B 10-K · filed 2018-02-08 | $2.43B derived: sum of 2 quarters · filed 2018-02-08 | $3.63B 10-Q · filed 2017-11-08 | $4.73B derived: sum of 4 quarters · filed 2018-02-08 |
| 2016-06-30 | $1.21B 10-K · filed 2018-02-08 | $2.41B 10-Q · filed 2017-08-03 | $3.51B derived: sum of 3 quarters · filed 2018-02-08 | $4.65B derived: sum of 4 quarters · filed 2018-02-08 |
| 2016-03-31 | $1.20B 10-K · filed 2018-02-08 | $2.30B derived: sum of 2 quarters · filed 2018-02-08 | $3.44B derived: sum of 3 quarters · filed 2018-02-08 | $4.43B derived: sum of 4 quarters · filed 2018-02-08 |
| 2015-12-31 | $1.10B 10-K · filed 2017-02-09 | $2.24B derived: sum of 2 quarters · filed 2017-02-09 | $3.23B derived: sum of 3 quarters · filed 2017-02-09 | $4.10B 10-K · filed 2018-02-08 |
| 2015-09-30 | $1.14B 10-K · filed 2017-02-09 | $2.14B derived: sum of 2 quarters · filed 2017-02-09 | $3.01B 10-Q · filed 2016-11-04 | $3.81B derived: sum of 4 quarters · filed 2017-02-09 |
| 2015-06-30 | $998.62M 10-K · filed 2017-02-09 | $1.87B 10-Q · filed 2016-08-04 | $2.67B derived: sum of 3 quarters · filed 2017-02-09 | $3.40B derived: sum of 4 quarters · filed 2017-02-09 |
| 2015-03-31 | $869.61M 10-K · filed 2017-02-09 | $1.67B derived: sum of 2 quarters · filed 2017-02-09 | $2.40B derived: sum of 3 quarters · filed 2017-02-09 | $3.06B derived: sum of 4 quarters · filed 2017-02-09 |
| 2014-12-31 | $802.33M 10-K · filed 2016-02-11 | $1.53B derived: sum of 2 quarters · filed 2016-02-11 | $2.19B derived: sum of 3 quarters · filed 2016-02-11 | $2.82B 10-K · filed 2017-02-09 |
| 2014-09-30 | $725.79M 10-K · filed 2016-02-11 | $1.39B derived: sum of 2 quarters · filed 2016-02-11 | $2.02B 10-Q · filed 2015-11-04 | $2.63B derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-06-30 | $665.70M 10-K · filed 2016-02-11 | $1.29B 10-Q · filed 2015-08-04 | $1.90B derived: sum of 3 quarters · filed 2016-02-11 | $2.50B derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-03-31 | $625.74M 10-K · filed 2016-02-11 | $1.24B derived: sum of 2 quarters · filed 2016-02-11 | $1.83B derived: sum of 3 quarters · filed 2016-02-11 | $2.29B derived: sum of 4 quarters · filed 2016-02-11 |
| 2013-12-31 | $610.41M 10-K · filed 2015-02-12 | $1.21B derived: sum of 2 quarters · filed 2015-02-12 | $1.67B derived: sum of 3 quarters · filed 2015-02-12 | $2.10B 10-K · filed 2016-02-11 |
| 2013-09-30 | $597.03M 10-K · filed 2015-02-12 | $1.05B derived: sum of 2 quarters · filed 2015-02-12 | $1.49B 10-Q · filed 2014-11-04 | $1.91B derived: sum of 4 quarters · filed 2015-02-12 |
| 2013-06-30 | $457.64M 10-K · filed 2015-02-12 | $897.31M 10-Q · filed 2014-08-05 | $1.31B derived: sum of 3 quarters · filed 2015-02-12 | $1.74B derived: sum of 4 quarters · filed 2015-02-12 |
| 2013-03-31 | $439.66M 10-K · filed 2015-02-12 | $854.27M derived: sum of 2 quarters · filed 2015-02-12 | $1.28B derived: sum of 3 quarters · filed 2015-02-12 | $1.59B derived: sum of 4 quarters · filed 2015-02-12 |
| 2012-12-31 | $414.60M 10-K · filed 2014-02-13 | $842.29M derived: sum of 2 quarters · filed 2014-02-13 | $1.15B derived: sum of 3 quarters · filed 2014-02-13 | $1.38B 10-K · filed 2015-02-12 |
| 2012-09-30 | $427.69M 10-K · filed 2014-02-13 | $732.09M derived: sum of 2 quarters · filed 2014-02-13 | $963.88M 10-Q · filed 2013-11-05 | $1.09B derived: sum of 4 quarters · filed 2014-02-13 |
| 2012-06-30 | $304.40M 10-K · filed 2014-02-13 | $536.19M 10-Q · filed 2013-08-06 | $659.16M derived: sum of 3 quarters · filed 2014-02-13 | $762.00M derived: sum of 4 quarters · filed 2014-02-13 |
| 2012-03-31 | $231.79M 10-K · filed 2014-02-13 | $354.77M derived: sum of 2 quarters · filed 2014-02-13 | $457.60M derived: sum of 3 quarters · filed 2014-02-13 | $565.41M derived: sum of 4 quarters · filed 2014-02-13 |
| 2011-12-31 | $122.98M 10-K · filed 2013-02-15 | $225.81M derived: sum of 2 quarters · filed 2013-02-15 | $333.62M derived: sum of 3 quarters · filed 2013-02-15 | $445.82M 10-K · filed 2014-02-13 |
| 2011-09-30 | $102.83M 10-K · filed 2013-02-15 | $210.64M derived: sum of 2 quarters · filed 2013-02-15 | $322.85M 10-Q · filed 2012-10-24 | $456.52M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-06-30 | $107.81M 10-K · filed 2013-02-15 | $220.01M 10-Q · filed 2012-07-25 | $353.69M derived: sum of 3 quarters · filed 2013-02-15 | $459.67M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-03-31 | $112.20M 10-K · filed 2013-02-15 | $245.88M derived: sum of 2 quarters · filed 2013-02-15 | $351.86M derived: sum of 3 quarters · filed 2013-02-15 | $467.74M derived: sum of 4 quarters · filed 2013-02-15 |
| 2010-12-31 | $133.68M 10-K · filed 2012-02-21 | $239.65M derived: sum of 2 quarters · filed 2012-02-21 | $355.54M derived: sum of 3 quarters · filed 2012-02-21 | $459.07M 10-K · filed 2013-02-15 |
| 2010-09-30 | $105.98M 10-K · filed 2012-02-21 | $221.87M derived: sum of 2 quarters · filed 2012-02-21 | $325.40M 10-Q · filed 2011-10-27 | $422.20M derived: sum of 4 quarters · filed 2012-02-21 |
| 2010-06-30 | $115.89M 10-K · filed 2012-02-21 | $219.42M 10-Q · filed 2011-07-28 | $316.22M derived: sum of 3 quarters · filed 2012-02-21 | $433.68M derived: sum of 4 quarters · filed 2012-02-21 |
| 2010-03-31 | $103.53M 10-K · filed 2012-02-21 | $200.33M derived: sum of 2 quarters · filed 2012-02-21 | $317.79M derived: sum of 3 quarters · filed 2012-02-21 | $407.82M derived: sum of 4 quarters · filed 2012-02-21 |
| 2009-12-31 | $96.80M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $214.25M derived: sum of 2 quarters · filed 2012-02-21 | $304.29M derived: sum of 3 quarters · filed 2012-02-21 | $379.27M 10-K · filed 2012-02-21 |
| 2009-09-30 | $117.45M 10-Q · filed 2010-10-28 | $207.49M derived: sum of 2 quarters · filed 2010-10-28 | $282.47M 10-Q · filed 2010-10-28 | |
| 2009-06-30 | $90.03M 10-Q · filed 2010-07-28 | $165.01M 10-Q · filed 2010-07-28 | ||
| 2008-12-31 | $238.46M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |